P1253: MAVORIXAFOR DISRUPTS THE CROSS TALK BETWEEN WALDENSTRÖM’S MACROGLOBULINEMIA CELLS AND THE BONE MARROW MICROENVIRONMENT RESULTING IN ENHANCED SENSITIVITY TO B-CELL TARGETED THERAPIES
H. Monticelli,
T. Kruitwagen,
M. Tardelli,
T. Rebelo,
B. Maierhofer,
S. Maier-Munsa,
K. Zmajkovicova,
A. G. Taveras,
C. Nguyen
Affiliations
H. Monticelli
1 X4 Pharmaceuticals (Austria) GmbH, Vienna, Austria
T. Kruitwagen
1 X4 Pharmaceuticals (Austria) GmbH, Vienna, Austria
M. Tardelli
1 X4 Pharmaceuticals (Austria) GmbH, Vienna, Austria
T. Rebelo
1 X4 Pharmaceuticals (Austria) GmbH, Vienna, Austria
B. Maierhofer
1 X4 Pharmaceuticals (Austria) GmbH, Vienna, Austria
S. Maier-Munsa
1 X4 Pharmaceuticals (Austria) GmbH, Vienna, Austria
K. Zmajkovicova
1 X4 Pharmaceuticals (Austria) GmbH, Vienna, Austria
A. G. Taveras
2 X4 Pharmaceuticals, Boston, United States of America
C. Nguyen
1 X4 Pharmaceuticals (Austria) GmbH, Vienna, Austria
